Clinical trials
Recurrent Solid Tumor clinical trials
Below are recruiting recurrent solid tumor clinical trials, each written for real people, not researchers. We’re tracking 460 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+ - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT05881525RecruitingPhase 1
Testing NY-ESO-1 T-cell therapy for advanced solid tumors
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
ChongqingAges 18–70 - NCT07256756RecruitingPhase 1
A study of GC203 TIL for advanced solid tumors
This trial tests a new treatment called GC203 TIL, which uses your own immune cells to fight advanced solid tumors. It's for people who have tried standard treatments and have a tumor that can be removed to create this therapy.
ShenzhenAges 18–75 - NCT07252414RecruitingPhase 1
Study of GenSci143 for advanced solid tumors
This trial tests a new drug, GenSci143, for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has spread or come back and you have no other standard options left.
Zhengzhou, HenanAges 18 years+ - NCT06796699RecruitingPhase 1
GH56 capsule study for MTAP-deleted advanced solid tumors
This study tests an experimental capsule (GH56) for people whose advanced solid tumors have a specific genetic change called MTAP deletion. The goal is to see if the capsule is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07110883RecruitingPhase 1
Study of SYS6023 for advanced solid tumors
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Harbin, HeilongjiangAges 18 years+ - NCT06819735RecruitingPhase 1/Phase 2
Testing DT-7012 in Advanced Solid Tumors
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combined therapy for advanced solid tumors
This trial tests a new drug combination for people with advanced solid tumors that are no longer responding to standard treatments. It focuses on patients whose tumors have high levels of a protein called CCNE1, particularly for certain ovarian, fallopian tube, peritoneal, and uterine cancers.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07259889RecruitingPhase 1
CEL001 injection safety study for advanced solid tumors
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
BeijingAges 18 years+ - NCT06907628RecruitingPhase 1
Testing SHR-3792 for advanced solid tumors
This trial tests a new drug called SHR-3792 for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and how it affects the tumors.
Jinan, ShandongAges 18–75 - NCT05867420RecruitingPhase 1/Phase 2
ASKG915 for advanced solid tumors that stopped responding
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
New York, New YorkAges 18 years+ - NCT07042100RecruitingPhase 1
Safety study of SBO-154 for advanced solid tumors
This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.
Scottsdale, ArizonaAges 18 years+ - NCT07348653RecruitingPhase 1
Study of MG2512 for advanced solid tumor patients
This trial tests a new drug called MG2512 for people with advanced solid tumors that have not responded to standard treatments or who cannot take standard therapy. The study aims to understand if MG2512 is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07446153RecruitingPhase 1/Phase 2
HRS-8364 for advanced solid tumors
This trial tests a new medicine, HRS-8364, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–75 - NCT06605222RecruitingPhase 1/Phase 2
Testing SHR-7787 for advanced solid tumors
This trial is testing an investigational drug called SHR-7787 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if it is safe and how well it works. It may be an option if your tumor type is no longer responding to other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07455734RecruitingPhase 1/Phase 2
Testing BNT3214 for advanced solid tumors
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
ClaytonAges 18 years+ - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Grand Rapids, MichiganAges 18 years+ - NCT07147348RecruitingPhase 1/Phase 2
BNT3212 alone or with BNT327 for advanced solid tumors
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
AdelaideAges 18 years+ - NCT07508761RecruitingPhase 1/Phase 2
IPG7236 with Toripalimab for advanced solid tumors
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Shanghai, PuDongXinQuAges 18 years+ - NCT07222969RecruitingPhase 1/Phase 2
Trial of VIB305 for advanced solid tumors
This trial tests a new drug called VIB305 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if VIB305 is safe and how it affects the tumors.
Sunshine CoastAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+
Hear when a new Recurrent Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent solid tumor?
- Yes. Clin2 currently lists 460 recruiting recurrent solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.